日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Consensus Guideline of Ablation for Metastatic Liver Tumors by Taiwan Academy of Tumor Ablation

台湾肿瘤消融学会制定的转移性肝肿瘤消融共识指南

Wu, Ming Shun; Kao, Wei-Yu; Chiang, Ming-Feng; Chuang, Po-Heng; Hsu, Shih-Jer; Wang, Shen-Yung; Chang, Ching-Wei; Lin, Chen-Chun; Hung, Chao-Hung; Wu, Chih Horng; Chen, San-Chi; Lee, Hsin-Lun; Hwang, Jen-I; Liang, Po-Chin; Lin, Shi-Ming; Wang, Chia-Chi

Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study

晚期肝细胞癌患者在接受阿特珠单抗联合贝伐珠单抗治疗后,再接受纳武利尤单抗联合伊匹木单抗治疗的疗效:一项国际多中心研究

Kim, Jung Sun; Wong, Jeffrey; Chen, San-Chi; Tai, David; Yang, Hannah; Kim, Youngun; Kang, Beodeul; Kim, Ilhwan; Kim, Hyeyeong; An, Chansik; Jang, Su Jin; Kudo, Masatoshi; Lim, Ho Yeong; Kim, Chan; Yau, Thomas; Chon, Hong Jae

Optimizing Systemic Therapy for Advanced Sarcomas: Outcomes With Gemcitabine, Docetaxel, Cisplatin, and Everolimus in a Retrospective Single-Center Study

优化晚期肉瘤全身治疗:回顾性单中心研究中吉西他滨、多西他赛、顺铂和依维莫司联合治疗的疗效

Wu, Wen-Chi; Ho, I-Wei; Chen, San-Chi; Chen, Paul Chih-Hsueh; Wu, Po-Kuei; Chen, Chao-Ming; Wu, Hung-Ta; Lin, Chung-Jung; Chao, Ta-Chung; Yen, Chueh-Chuan

Complete Remission of Hepatocellular Carcinoma With Atezolizumab and Bevacizumab Following Prior B-cell Depletion

既往接受B细胞清除治疗后,使用阿特珠单抗和贝伐珠单抗治疗可使肝细胞癌完全缓解

Huang, Jen-Pei; Tsai, Chun-Kuang; Hsieh, Pei-Ying; Chen, San-Chi

Predicting Survival Outcomes in Patients with Hepatocellular Carcinoma Receiving Lenvatinib by Using the Up7-ALBI Score

利用 Up7-ALBI 评分预测接受乐伐替尼治疗的肝细胞癌患者的生存结局

Lu, Chien-Hung; Kao, Wei-Yu; Wu, Chih-Horng; Ting, Wei-Yi; Lu, Chia-Hsun; Chuang, Kai-I; Ni, Cheng-Fu; Hsieh, Yao-Yu; Wu, Ming-Shun; Su, Chien-Wei; Chen, San-Chi

Circulating miRNAs as potentially predictive biomarkers for chemoimmunotherapy in advanced biliary tract cancer: a post-hoc analysis of the phase II T1219 study.

循环 miRNA 作为晚期胆道癌化疗免疫疗法的潜在预测生物标志物:II 期 T1219 研究的事后分析

Chiang Nai-Jung, Tang Cheng-Yu, Bai Li-Yuan, Chang Po-Chang, Chen Wei-Ming, Kang Shih-Ting, Chen San-Chi, Chen Ming-Huang, Hsieh Jason Chia-Hsun

The correlation between LAG-3 expression and the efficacy of chemoimmunotherapy in advanced biliary tract cancer

LAG-3表达与晚期胆道癌化疗免疫疗法疗效的相关性

Tang, Cheng-Yu; Lin, Yi-Ting; Yeh, Yi-Chen; Chung, Shin-Yi; Chang, Yu-Chan; Hung, Yi-Ping; Chen, San-Chi; Chen, Ming-Huang; Chiang, Nai-Jung

Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer

在多中心队列研究中,度伐利尤单抗联合化疗治疗晚期胆道癌的真实世界疗效及预后因素

Huang, Wen-Kuan; Tang, Yan-Jei; Wu, Chiao-En; Hou, Ming-Mo; Hsu, Hung-Chih; Su, Po-Jung; Chiang, Nai-Jung; Chen, San-Chi; Yeh, Chun-Nan; Chen, Jen-Shi; Chen, Ming-Huang; Hsieh, Chia-Hsun; Chou, Wen-Chi

Efficacy of atezolizumab combined with platinum and etoposide in the treatment of extrapulmonary neuroendocrine carcinoma

阿特珠单抗联合铂类和依托泊苷治疗肺外神经内分泌癌的疗效

Ho, I-Wei; Chiang, Nai-Jung; Lai, Jiun-I; Chang, Peter Mu-Hsin; Chen, San-Chi; Hung, Yi-Ping; Chen, Ming-Huang

Machine Learning-Based Survival Analysis for Patients Receiving Lenvatinib for Unresectable Hepatocellular Carcinoma

基于机器学习的不可切除肝细胞癌患者接受乐伐替尼治疗的生存分析

Lu, Chien-Hung; Chang, Ching-Wen; Chen, San-Chi; Kao, Wei-Yu; Ting, Wei-Yi; Lu, Chia-Hsun; Chuang, Kai-I; Ni, Cheng-Fu; Hsieh, Yao-Yu; Wu, Ming-Shun; Su, Chien-Wei; Chang, Chun-Chao; Wu, Chih-Horng